JP2008514209A - 癌マーカー - Google Patents

癌マーカー Download PDF

Info

Publication number
JP2008514209A
JP2008514209A JP2007533908A JP2007533908A JP2008514209A JP 2008514209 A JP2008514209 A JP 2008514209A JP 2007533908 A JP2007533908 A JP 2007533908A JP 2007533908 A JP2007533908 A JP 2007533908A JP 2008514209 A JP2008514209 A JP 2008514209A
Authority
JP
Japan
Prior art keywords
gene
cancer
numb
protein
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007533908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008514209A5 (https=
Inventor
ピエル・パオイオ・ディ・フィオレ
ペチェ・サルヴァトーレ
イアン・マルク・ボナパチェ
フランチェスコ・ニカッシオ
ファブリツィオ・ビアンキ
マヌエラ・ヴェッキ
ステファノ・コンファロニエリ
Original Assignee
イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ filed Critical イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ
Publication of JP2008514209A publication Critical patent/JP2008514209A/ja
Publication of JP2008514209A5 publication Critical patent/JP2008514209A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007533908A 2004-09-30 2005-09-20 癌マーカー Pending JP2008514209A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0421838.4A GB0421838D0 (en) 2004-09-30 2004-09-30 Cancer markers
PCT/EP2005/010153 WO2006037462A2 (en) 2004-09-30 2005-09-20 Cancer markers

Publications (2)

Publication Number Publication Date
JP2008514209A true JP2008514209A (ja) 2008-05-08
JP2008514209A5 JP2008514209A5 (https=) 2008-10-16

Family

ID=33427903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007533908A Pending JP2008514209A (ja) 2004-09-30 2005-09-20 癌マーカー

Country Status (7)

Country Link
US (1) US7901876B2 (https=)
EP (2) EP1802971A2 (https=)
JP (1) JP2008514209A (https=)
AU (1) AU2005291613A1 (https=)
CA (1) CA2581041A1 (https=)
GB (1) GB0421838D0 (https=)
WO (1) WO2006037462A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2016117466A1 (ja) * 2015-01-22 2017-11-02 コニカミノルタ株式会社 生体物質定量方法、病理診断支援システム及びプログラム

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8747867B2 (en) 2004-09-30 2014-06-10 Ifom Fondazione Instituto Firc Di Oncologia Molecolare Cancer markers
US7919092B2 (en) * 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
EP2125887A4 (en) 2007-01-24 2010-11-10 Oncomed Pharm Inc COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
WO2008100563A2 (en) * 2007-02-14 2008-08-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2010520280A (ja) * 2007-03-05 2010-06-10 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
WO2010132861A2 (en) 2009-05-14 2010-11-18 Duke University Diagnostic and treatment for chronic and acute phase myeloid leukemia
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
WO2013155077A1 (en) * 2012-04-09 2013-10-17 Board Of Regents,The University Of Texas System Response markers for src inhibitor therapies
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
CN109266740A (zh) * 2017-07-14 2019-01-25 中国科学院上海生命科学研究院 用于肺癌诊断或预后的标志物及诊断试剂
CN114606320B (zh) * 2022-04-13 2023-06-16 重庆医科大学 生物标志物epn3在制备诊断或评估肺癌的产品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004531216A (ja) * 2000-12-26 2004-10-14 モレキュラー、エンジンズ、ラボラトリーズ Ｓｉａｈ−ｎｕｍｂ相互作用に基づくスクリーニング法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380777D1 (en) 1982-08-27 1989-11-30 Roger Philip Ekins Measurement of analyte concentration
WO1988001058A1 (en) 1986-08-06 1988-02-11 Roger Philip Ekins Determination of analyte concentration using two labelling markers
GB8803000D0 (en) 1988-02-10 1988-03-09 Ekins Roger Philip Determination of ambient concentrations of several analytes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69223980T2 (de) 1991-10-15 1998-05-28 Multilyte Ltd Bindungstest unter benutzung eines markierten reagens
GB9326450D0 (en) 1993-12-24 1994-02-23 Multilyte Ltd Binding assay
GB9326451D0 (en) 1993-12-24 1994-02-23 Multilyte Ltd Binding assay
GB9404709D0 (en) 1994-03-11 1994-04-27 Multilyte Ltd Binding assay
GB9815799D0 (en) 1998-07-21 1998-09-16 Pharmagene Lab Limited Quantitative analysis of gene expression
AU768269B2 (en) * 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
JP2005500832A (ja) 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
WO2003011317A1 (en) 2001-07-25 2003-02-13 Lorantis Limited Modulators of notch signalling for use in immunotherapy
WO2003042246A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
WO2003088910A2 (en) 2002-04-15 2003-10-30 Rigel Pharmaceuticals, Inc. Methods of assaying for cell cycle modulators
US20050272061A1 (en) * 2004-02-19 2005-12-08 Seattle Genetics, Inc. Expression profiling in non-small cell lung cancer
US7837993B2 (en) * 2004-03-19 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for regeneration of aged skeletal muscle tissues
US20060068434A1 (en) * 2004-09-21 2006-03-30 Jay Stoerker Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004531216A (ja) * 2000-12-26 2004-10-14 モレキュラー、エンジンズ、ラボラトリーズ Ｓｉａｈ−ｎｕｍｂ相互作用に基づくスクリーニング法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2016117466A1 (ja) * 2015-01-22 2017-11-02 コニカミノルタ株式会社 生体物質定量方法、病理診断支援システム及びプログラム
US10746740B2 (en) 2015-01-22 2020-08-18 Konica Minolta, Inc. Biological substance quantitation method, pathological diagnosis support system, and recording medium storing computer readable program

Also Published As

Publication number Publication date
WO2006037462A3 (en) 2006-07-13
GB0421838D0 (en) 2004-11-03
EP1802971A2 (en) 2007-07-04
US7901876B2 (en) 2011-03-08
WO2006037462A2 (en) 2006-04-13
EP2249155A2 (en) 2010-11-10
EP2249155A3 (en) 2011-03-16
US20080188405A1 (en) 2008-08-07
CA2581041A1 (en) 2006-04-13
AU2005291613A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
KR102442275B1 (ko) 암 전이의 예후 및 치료 방법
DK2859120T3 (en) Method for diagnosis and prognosis of lung cancer metastasis
JP6148007B2 (ja) 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７
AU2014333513B2 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
JP2008514209A (ja) 癌マーカー
KR20150122731A (ko) 암 전이의 예후 및 치료 방법
Ouyang et al. COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer
WO2013006495A2 (en) Methods of predicting prognosis in cancer
Maliszewska et al. Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions
Silveira et al. Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries
US8029984B2 (en) Materials and methods for colorectal cancer screening, diagnosis and therapy
JP2007512807A (ja) 悪性腫瘍の処置に対する応答予測のための方法および組成物
Fujiwara et al. The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2-breast cancer
Li et al. Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene
WO2011123427A2 (en) Treatment of cancer by inhibiting activity or expression of late sv-40 factor
EP2433134B1 (en) Assay methods for the determination of fkbpl expression level in the context of breast cancer
BR112013003506B1 (pt) Método para detectar a presença de uma isoforma de bard1 e método para discriminar câncer
US8747867B2 (en) Cancer markers
KR101358810B1 (ko) 방사선 피폭 진단용 마커 ｉｇｆｂｐ-5, 그 마커의 발현수준을 측정하는 방사선 피폭 진단용 조성물, 그 조성물을 포함하는 방사선 피폭 진단용 키트, 및 그 마커를 이용한 방사선 피폭을 진단하는 방법
EP2721178B1 (en) Method for the prognosis of breast cancer based on expression markers
WO2010123124A1 (ja) 固形がんの再発および予後因子、およびその臨床利用
JP7353608B2 (ja) Ａｄａｍｔｓｌ５遺伝子の過剰発現に基づく癌の診断および治療のための方法およびキット
US10942183B2 (en) Methods of detecting progesterone receptor and of detecting an expression level
WO2008125791A1 (en) Cancer markers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111025